His primary areas of study are Positron emission tomography, Pathology, Nuclear medicine, In vivo and Integrin. His Positron emission tomography study is concerned with Radiology in general. His Pathology study combines topics in areas such as Fluorodeoxyglucose, Cancer and Beta.
The concepts of his Nuclear medicine study are interwoven with issues in Pharmacokinetics, Head and neck cancer, Hypoxia and Biodistribution. He has included themes like Cancer research, In vitro, Peptide, Biochemistry and Molecular biology in his In vivo study. His Integrin research is multidisciplinary, incorporating elements of Angiogenesis, Renal cell carcinoma, Cell adhesion, Cell biology and Pet imaging.
Hans-Jürgen Wester mainly investigates Positron emission tomography, In vivo, Pathology, Nuclear medicine and Biodistribution. His Positron emission tomography research focuses on subjects like Prostate cancer, which are linked to Lymph node. His In vivo research includes elements of Receptor, Molecular biology, In vitro and Stereochemistry.
His study on Pathology also encompasses disciplines like
The scientist’s investigation covers issues in Prostate cancer, Positron emission tomography, CXCR4, In vivo and PET-CT. His biological study spans a wide range of topics, including Lymph node and Urology. His Positron emission tomography research is multidisciplinary, incorporating perspectives in Internal medicine, Malignancy, Oncology, Molecular imaging and Magnetic resonance imaging.
His CXCR4 research includes themes of Immunohistochemistry, Pathology, Cancer research and Chemokine receptor. Hans-Jürgen Wester specializes in In vivo, namely Biodistribution. Hans-Jürgen Wester combines subjects such as Integrin and Peptide with his study of Molecular biology.
His primary areas of investigation include Prostate cancer, Positron emission tomography, PET-CT, CXCR4 and Biochemical recurrence. His studies in Prostate cancer integrate themes in fields like Radiology, Radiation therapy and Oncology. Hans-Jürgen Wester has researched Positron emission tomography in several fields, including Neuroendocrine tumors, Recurrent prostate cancer and Somatostatin receptor.
His PET-CT study introduces a deeper knowledge of Nuclear medicine. The various areas that Hans-Jürgen Wester examines in his CXCR4 study include Cancer research, Chemokine receptor and Pathology. His studies deal with areas such as Biodistribution, In vivo, Neuroscience and Review article as well as Receptor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy
Matthias Eiber;Tobias Maurer;Michael Souvatzoglou;Ambros J. Beer.
The Journal of Nuclear Medicine (2015)
Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography
Roland Haubner;Hans-Jürgen Wester;Wolfgang A. Weber;Christian Mang.
Cancer Research (2001)
Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer
Tobias Maurer;Jürgen E. Gschwend;Isabel Rauscher;Michael Souvatzoglou.
The Journal of Urology (2016)
Glycosylated RGD-Containing Peptides: Tracer for Tumor Targeting and Angiogenesis Imaging with Improved Biokinetics
Roland Haubner;Hans-Jürgen Wester;Fred Burkhart;Reingard Senekowitsch-Schmidtke.
The Journal of Nuclear Medicine (2001)
Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD
Roland Haubner;Wolfgang A Weber;Ambros J Beer;Eugenija Vabuliene.
PLOS Medicine (2005)
Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting
Roland Haubner;Hans-Jürgen Wester;Ute Reuning;Reingard Senekowitsch-Schmidtke.
The Journal of Nuclear Medicine (1999)
O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study.
Wolfgang A. Weber;Hans-Jürgen Wester;Anca L. Grosu;Michael Herz.
European Journal of Nuclear Medicine and Molecular Imaging (2000)
[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates.
Roland Haubner;Bertrand Kuhnast;Christian Mang;Wolfgang A Weber.
Bioconjugate Chemistry (2004)
Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man
Ambros J. Beer;Roland Haubner;Mario Sarbia;Michael Goebel.
Clinical Cancer Research (2006)
Hypoxia-Specific Tumor Imaging with 18F-Fluoroazomycin Arabinoside
Morand Piert;Hans Jürgen Machulla;Maria Picchio;Gerald Reischl.
The Journal of Nuclear Medicine (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: